Evidence map›Paper›PMID 42693162›Full record

ArticleLeukemia2026

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Stephani Schmitz, Juliette E Pearce, Sergio Martinez-Høyer, Gerjanne Vroeg In de Wei, Inge A M Snoeren, Ursula S A Stalmann, Stijn N R Fuchs, Aurelien J F Dugourd, Giulia Franciosa, Eric M Bindels and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Stephani Schmitz *Department of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.
Juliette E Pearce *Department of Cell and Tumor Biology, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0001-8155-6534
Sergio Martinez-HøyerDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0074-5726
Gerjanne Vroeg In de WeiDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.
Inge A M SnoerenDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.
Ursula S A StalmannDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.
Stijn N R FuchsDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.
Aurelien J F DugourdHeidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany.
Giulia FranciosaNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-5309-5558
Eric M BindelsDepartment of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9502-669X
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-5083-9838
Claudia MeyerDepartment of Medicine V, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0003-0196-2837
Emiel P C van der VorstDepartment of Internal Medicine I - Cardiology, Uniklinik RWTH Aachen, RWTH Aachen University, Aachen, Germany.
Oriol CalveteMDS Group, Josep Carreras Leukaemia Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain.ORCID http://orcid.org/0000-0002-2623-2876
Francesc SoléMDS Group, Josep Carreras Leukaemia Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain.
Julio Saez-RodriguezHeidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8552-8976
Andreas LinkermannDepartment of Medicine V, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0001-6287-9725
Jesper OlsenNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4747-4938
Hélène F E GleitzDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6138-8916
Rebekka K SchneiderDepartment of Developmental Biology, Erasmus Medical Center, Rotterdam, The Netherlands. reschneider@ukaachen.de.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 417911533Deutsche Forschungsgemeinschaft (German Research Foundation) 504777725; 417911533; 514007497Deutsche Forschungsgemeinschaft (German Research Foundation) INST 222/1598-1 FUGG Projekt 566187929EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj) PMP 24/00025EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101124542; 757339; PoC DeAlarmin; 953407EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) INTERCEPT-MDS ITN 953407Generalitat de Catalunya (Government of Catalonia) 2021 SGR 00560Generalitat de Catalunya (Government of Catalonia) CERCA ProgrammeJosé Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) DJCLS 01 R/2021; 2021-20250José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) PI 23/0007ZonMw (Netherlands Organisation for Health Research and Development) 09150172110021
6 · The paper itself

Abstract

Deletion of chromosome 5q [del(5q)] is the most common cytogenetic abnormality in myelodysplastic neoplasms (MDS) and results in haploinsufficiency of multiple genes, including CSNK1A1. Recurrent CSNK1A1 mutations, predominantly affecting the E98 hotspot, occur almost exclusively in del(5q) MDS and are associated with adverse outcomes, yet their impact on CK1ɑ function remains unclear. Using integrated transcriptomic, (phospho)proteomic, and kinome activity profiling in hematopoietic stem and progenitor cells (HSPCs), combined with in vivo serial transplantation assays, we show that Csnk1a1 E98V represents a change-of-function rather than a loss-of-function mutation. Unlike Csnk1a1 haploinsufficiency, Csnk1a1 E98V preserves long-term hematopoietic reconstitution and does not enhance clonal expansion in vivo. Instead, the mutation induces suppression of kinase signaling networks, leading to coordinated repression of ribosomal gene expression, protein translation, and cell cycle programs. This signaling rewiring is accompanied by metabolic reprogramming characterized by reduced mitochondrial respiration, increased glycolytic flux, and an inability to adapt to metabolic challenges, creating a stress-tolerant but inflexible cellular state. Notably, Csnk1a1 E98V cells exhibit impaired megakaryopoiesis and increased vulnerability to iron overload, as well as RSL-3-mediated ferroptosis. Analysis of del(5q) MDS patients confirmed that CSNK1A1 mutations are associated with distinct clinical features, including thrombocytopenia, elevated myeloblasts, and reduced bone marrow iron levels. Together, our findings support a two-step model in which del(5q)-associated CSNK1A1 haploinsufficiency drives clonal expansion, followed by acquisition of CSNK1A1 mutations that promote stress tolerance rather than increased proliferation. This adaptive rewiring exposes metabolic and iron-dependent vulnerabilities that may be therapeutically exploited.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.